Abstract: Background and Objective: Breviscapine considered to be an active ingredient of flavonoids and able to dilate the blood vessels, reduce vascular resistance, increase blood flow, improve microcirculation and suppress the aggregation of platelets. This study was assessed the therapeutic effect of breviscapine in combination with methylcobalamin in the management of diabetic peripheral nephropathy. Materials and Methods: The sample size of 300 subjects was taken and subdivided equally into 2 groups. Treatment group subjects were given a breviscapine oral dosage of 20 mg/day and a tablet of Vitamin B which further contained the 2 mg dL–1 of folic acid and 1 mg dL–1 of methylcobalamin. The therapy was given for continuous 12 months and followed up for 36 months. Another group had taken as a placebo group and received a dosage of 1 mg dL–1 of methylcobalamin only. Glomerular filtration rate (GFR) was taken as primary level outcome. Results: Increased radionuclide GFR was 6.2 mL min–1/1.73 m2 in the treatment group at 18 months and 10.8 mL min–1/1.73 m2 at 36 months and decreased to -3.1 mL min–1/1.73 m2 at 18 months and -5.7 mL min–1/1.73 m2 at 36 months in the placebo group. So, a higher level of radionuclide GFR at 18 months and at 36 months was found in the treatment group when compared with the baseline level and placebo with significant p-value of less than 0.05. Conclusion: So it was concluded that the breviscapine improves the diabetic nephropathy sign and symptoms and also improves the quality of life of the subjects.